

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/667,931		ATTY. DOCKET NO.: N0469.70022US02	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: September 22, 2003		CONFIRMATION NO.: 1625	
				APPLICANT: Poh K. Hui			
				GROUP ART UNIT: 1625		EXAMINER: Gollamudi S. Kishore	
Sheet	1	of	4				

U.S. PATENT DOCUMENTS

Examiner's Initials [§]	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		3,945,956		Garner	03-23-1976
		4,515,736		Deamer	05-07-1985
		4,636,381		Takada et al.	01-13-1987
		4,646,756		Watmough et al.	03-03-1987
		4,680,171		Shell	07-14-1987
		4,683,092		Tsang	07-28-1987
		4,722,943		Melber et al.	02-02-1988
		4,748,216		Tom	05-31-1998
		4,753,788		Gamble	06-28-1988
		4,880,635		Janoff et al.	11-14-1989
		4,946,787		Eppstein et al.	08-07-1990
		4,957,656		Cerny et al.	09-18-1990
		4,978,483		Redding, Jr.	12-18-1990
		5,006,343		Benson et al.	04-09-1991
		5,089,181		Hauser	02-18-1992
		5,091,188		Haynes	02-25-1992
		5,100,662		Bolcsak et al.	03-31-1992
		5,171,577		Griat et al.	12-15-1992
		5,171,678		Behr et al.	12-15-1992
		5,205,287		Erbel et al.	04-27-1993
		5,246,707		Haynes	09-21-1993
		5,264,618		Felgner et al.	11-23-1993
		5,279,833		Rose	01-18-1994
		5,283,185		Epad et al.	02-01-1994
		5,334,761		Gebeyehu et al.	08-02-1994
		5,348,016		Unger et al.	09-20-1994
		5,695,741		Schutt et al.	12-09-1997
		5,730,954		Albayrak et al.	03-24-1998
		5,879,659		Edwards et al.	03-09-1999
		5,965,109		Lohrmann	10-12-1999
		5,368,840		Unger	11-29-1994

EXAMINER:	DATE CONSIDERED:
-----------	------------------

[§] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/667,931	ATTY. DOCKET NO.: N0469.70022US02
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: September 22, 2003	CONFIRMATION NO.: 1625
				APPLICANT: Poh K. Hui	
				GROUP ART UNIT: 1625	EXAMINER: Gollamudi S. Kishore
Sheet	2	of	4		

FOREIGN PATENT DOCUMENTS

Examiner's Initials *	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		EP	0 382 619	A1	Oreal	02-09-1989	See US 5,171,577*
		EP	0 561 424	A1	The Liposome Company, Inc.	09-22-1993	
		EP	0 562 641	A1	The Liposome Company, Inc.	09-29-1993	
		EP	0 957 942	B1	Acusphere Inc.	06-16-2004	
		JP	8-151335	A	Otsuka Pharma Co., Ltd.	06-11-1996	Y-Claims only
		WO	89/10118	A1	Hemagen Pfc	11-02-1989	
		WO	90/14846	A1	Alliance Pharma et al.	12-13-1990	
		WO	91/15753	A1	Unger	10-17-1991	
		WO	93/09762	A2	Long David M Jr et al.	05-27-1993	
		WO	94/028874	A1	Unger et al.	12-22-1994	
		WO	95/12387	A1	Amgen Inc	05-11-1995	
		WO	95/16467	A1	Bracco Research S.A.	06-22-1995	
		WO	97/40679	A1	Imarx Pharmaceutical Corp	11-06-1997	

* U.S. 5,171,577 claiming same priority as EP 0 382 619

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] Division of new drug chemistry document relating to Definity. Review date, February 15, 2001.	
		[No Author Listed] EMEA Scientific discussion relating to Sonovue. Updated until October 1, 2004. 1 page.	
		[No Author Listed] http://www.acusphere.com/product/prod/_imagify.html .	
		[No Author Listed] Pages from DuPont website relating to FREON. Last accessed online at http://www.dupont.com/msds/40_37_2011fr.html on February 15, 2002. 5 pages.	
		ARAI et al., Transpulmonary passage of Acrosomes®, a pressure stable, lipid based echocardiographic contrast agent: studies in pigs. J Am Coll Cardiol. 1994;23-25A. Abstract only.	
		BOTVINICK, Stress imaging: current clinical options for the diagnosis, localization, and evaluation of coronary artery disease. Contemporary Issues Cardiol. Sept 1995;79(5):1025-57.	
		BURN et al., Stress echocardiography. Q J med. 1995;88:755-61.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/667,931	ATTY. DOCKET NO.: N0469.70022US02
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: September 22, 2003	CONFIRMATION NO.: 1625
				APPLICANT: Poh K. Hui	
				GROUP ART UNIT: 1625	EXAMINER: Gollamudi S. Kishore
Sheet	3	of	4		

	CHENG et al., "The Production and Evaluation of Contrast-Carrying Liposomes Made with an Automatic High Pressure System", Investigative Radiology, vol. 22, No. 1, pp. 47-55 (1987).
	DE JONG et al., New ultrasound contrast agents and technological innovations, Ultrasonics, 1996 Jun;34(2-5):587-90.
	GAENTZLER et al., "Perfluoroalkylated Phosphocholines. Improved Synthesis, Surface Activity, Fluorocarbon Emulsifying Capability and Biological Properties", New Journal of Chemistry 1993, 17(5), 337-344.
	Galjee, Biosis #91:493622, 1991.
	GROSS, U. et al., "Phospholipid vesiculated fluorocarbons promising trend in blood substitutes" Biomater., Art. Cells & Immo. Biotech., 1992, vol. 20, (2-4) pp 831-833.
	HAYAT et al., Effects of left bundle-branch block on cardiac structure, function, perfusion, and perfusion reserve: implications for myocardial contrast echocardiography versus radionuclide perfusion imaging for the detection of coronary artery disease, Circulation. 2008 Apr 8;117(14):1832-41. Epub 2008 Mar 31.
	KAUL, Myocardial contrast echocardiography in coronary artery disease: potential applications using venous injections of contrast. Am J Cardiol. 1995 Apr 13;75(11):61D-68D.
	O'KEEFE et al., Comparison of stress echocardiography and stress myocardial perfusion scintigraphy for diagnosing coronary artery disease and assessing its severity. Am J Cardiol. 1995 Apr 13;75(11):25D-34D.
	OTIS et al., Contrast-enhanced transcranial imaging. Results of an American phase-two study. Stroke. 1995 Feb;26(2):203-9.
	PAPAHADJOPOULOS et al., Sterically stabilized liposomes:improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4.
	REGEN et al., Polymerized phosphatidylcholine vesicles. Synthesis and characterization. J Am Chem Soc. 1982;104:791-5.
	RIESS, J.G., "Fluorine in our arteries," New J.Chem., XP-000990897, 1995, 19, 891-909 (English abstract).
	RIESS, J.G., "Introducing a new element-fluorine-into the liposomal membrane", Liposome Res., 1995, XP-000525914, 5(3), 413-430.
	SANTAELLA, C. et al., "Emulsification of Fluorocarbons Using Perfluoroalkylated Glycerophosphocholines as Surfactants or Co-Surfactants", New J. Chem., 1992, 16(3), 399-404.
	Seibyl, Biois #94:339104, 1994.
	SENIOR et al., RAMP-1 and RAMP-2 Investigators. Detection of coronary artery disease with perfusion stress echocardiography using a novel ultrasound imaging agent: two Phase 3 international trials in comparison with radionuclide perfusion imaging. Eur J Echocardiogr. 2009 Jan;10(1):26-35.
	SENIOR, Imagify (perflubutane polymer microspheres) injectable suspension for the assessment of coronary artery disease, Expert Rev Cardiovasc Ther. 2007 May;5(3):413-21.
	SHINODA, K. et al., "Colloidal Surfactants; Some Physiochemical Properties", Chapter 1, pp. 1-96, Academic Press, New York, 1963.
	SOLE-VIOLAN, L., "Partition Coefficients of Mixed Fluorocarbon-Hydrocarbon Compounds Between Fluorocarbons and Hexadecane. Relevance of Fluorocarbon Emulsion Stabilization", New J. Chem., 1993, 17(8,9), 581-583.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/667,931	ATTY. DOCKET NO.: N0469.70022US02
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: September 22, 2003	CONFIRMATION NO.: 1625
				APPLICANT: Poh K. Hui	
				GROUP ART UNIT: 1625	EXAMINER: Gollamudi S. Kishore
Sheet	4	of	4		

		SONNE et al., Left ventricular opacification after intravenous injection of Albunex. The effect of different administration procedures. <i>Int J Card Imaging</i> . 1995 Mar;11(1):47-53.	
		SUTHERLAND et al., "Color Doppler Myocardial Imaging: A New Technique for the Assessment of Myocardial Function", <i>J. Am. Soc. Of Echocardiogr</i> . 1994, 7(5), 441-458.	
		TREVINO, L, et al., "Incorporation of a perfluoroalkylalkane (rfth) into the phospholipid bilayer of dmpe liposomes results in greater encapsulation stability", <i>Journal of Liposome Research</i> . 1994, vol. 4 (2) pp 1017-1028.	
		TSUTSUI et al., Comparison of low-mechanical index pulse sequence schemes for detecting myocardial perfusion abnormalities during vasodilator stress echocardiography. <i>Am J Cardiol</i> . 2005 Mar 1;95(5):565-70.	
		Uemura, <i>Biosis</i> #80: 105491, 1979.	
		Uemura, <i>Embuse</i> , #79180131, 1979.	
		ULENDORF, "Physics of Ultrasound Contrast Imaging: Scattering in the Linear Range", <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 1994, 41(1), 70-79.	
		YU et al., Incremental value of parametric quantitative assessment of myocardial perfusion by triggered Low-Power myocardial contrast echocardiography. <i>J Am Coll Cardiol</i> . 2004 May 19;43(10):1807-13.	
		ZARIF, L. et al., "Biodistribution and excretion of a mixed 4fluorocarbon-hydrocarbon "dowel" emulsion as determined by 19-F NMR", <i>Artificial Cells, Blood Substitutes, and Immobilization Biotechnology</i> , 1994, vol. 22,(4) pp 1193-1198.	

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR § 1.98 and 12870G163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR § 1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR § 1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. § 120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

⁸ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.